Study directory

Depression studies

Compare studies and check their requirements with the research team.

6115studies shown

Showing 1,765-1,776 of 6,115

CompletedEUCTR 2014-000379-14

A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Germany, Poland
Sponsor: Alkermes, Inc.
Condition: Depression

View study

CompletedEUCTR 2019-002704-41

A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with par...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Belgium, Bulgaria, Czechia, ...
Sponsor: H. Lundbeck A/S
Condition: Depression

View study

TerminatedEUCTR 2014-000129-19

A randomized , double-blind, placebo-controlled study of antidepressant effects of the endogen compound neuropeptide y (NPY) in patients suffering from major depressive disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Sweden

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Sweden
Sponsor: Karolinska University Hospital, Huddinge
Condition: Depression

View study

CompletedEUCTR 2011-005878-37

A randomized, double-blind study comparing the efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Austria, Czechia, Italy, ...
Sponsor: ANGELINI
Condition: Depression

View study

CompletedEUCTR 2017-005149-64

A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Finland, Poland
Sponsor: Minerva Neurosciences, Inc
Condition: Depression

View study

TerminatedEUCTR 2018-000063-88

A Randomized, Double-blind, Placebo- and Active- controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Sweden
Sponsor: Allergan Ltd.
Condition: Depression

View study

CompletedEUCTR 2021-001212-29

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Finland, Poland, ...
Sponsor: Intra-Cellular Therapies, Inc.
Condition: Depression

View study

CompletedEUCTR 2004-000167-95

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Germany, Italy, Sweden
Sponsor: Eli Lilly and Company Limited
Condition: Depression

View study

CompletedEUCTR 2010-023576-10

Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day giv...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Romania
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

CompletedEUCTR 2010-024191-25

Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Austria, Germany
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

CompletedEUCTR 2007-003312-65

Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, interna...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France, Czechia, Estonia, ...
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

CompletedEUCTR 2009-011238-84

Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe Major Depressive Disorder. A 6...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Finland, Slovakia
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.